- Updated preclinical data will be presented on CRISPR/Cas9-mediated targeted gene insertion to treat alpha-1 antitrypsin deficiency (AATD)

Read more here:
Intellia Therapeutics Announces Presentations at the 24th American Society of Gene and Cell Therapy Annual Meeting

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *